Opinion | Published:

BRCAness revisited

Nature Reviews Cancer volume 16, pages 110120 (2016) | Download Citation


Over the past 20 years, there has been considerable progress in our understanding of the biological functions of the BRCA1 and BRCA2 cancer susceptibility genes. This has led to the development of new therapeutic approaches that target tumours with loss-of-function mutations in either BRCA1 or BRCA2. Tumours that share molecular features of BRCA-mutant tumours — that is, those with 'BRCAness' — may also respond to similar therapeutic approaches. Several paradigm shifts require a reassessment of the concept of BRCAness, how this property is assayed and its relevance to our understanding of tumour biology and the treatment of cancer.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from $8.99

All prices are NET prices.


  1. 1.

    , & Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science 343, 1466–1470 (2014).

  2. 2.

    “The race” to clone BRCA1. Science 343, 1462–1465 (2014).

  3. 3.

    Cancer suppression by the chromosome custodians, BRCA1 and BRCA2. Science 343, 1470–1475 (2014).

  4. 4.

    , , & Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb. Perspect.Biol. 7, a016600 (2015).

  5. 5.

    & The DNA damage response and cancer therapy. Nature 481, 287–294 (2012).

  6. 6.

    , , & Wip1 controls global heterochromatin silencing via ATM/BRCA1-dependent DNA methylation. Cancer Cell 24, 528–541 (2013).

  7. 7.

    et al. Identification of a BRCA1–mRNA splicing complex required for efficient DNA repair and maintenance of genomic stability. Mol. Cell 54, 445–459 (2014).

  8. 8.

    et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J. 20, 4704–4716 (2001).

  9. 9.

    et al. Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining. Proc. Natl Acad. Sci. USA 98, 8644–8649 (2001).

  10. 10.

    , & BRCA2 is required for homology-directed repair of chromosomal breaks. Mol. Cell 7, 263–272 (2001).

  11. 11.

    , & Hallmarks of 'BRCAness' in sporadic cancers. Nat. Rev. Cancer 4, 814–819 (2004).

  12. 12.

    et al. A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity. PLoS ONE 8, e61520 (2013).

  13. 13.

    et al. Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors. Mol. Cancer Res. 13, 1465–1477 (2015).

  14. 14.

    et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 72, 5588–5599 (2012).

  15. 15.

    et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol. Cancer Ther. 13, 433–443 (2014).

  16. 16.

    et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).

  17. 17.

    et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005).

  18. 18.

    et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123–134 (2009).

  19. 19.

    et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376, 235–244 (2010).

  20. 20.

    et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376, 245–251 (2010).

  21. 21.

    et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 366, 1382–1392 (2012).

  22. 22.

    et al. FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin. Cancer Res. 21, 4257–4261 (2015).

  23. 23.

    & Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat. Med. 19, 1381–1388 (2013).

  24. 24.

    et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov. 3, 68–81 (2013).

  25. 25.

    et al. REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature 521, 541–544 (2015).

  26. 26.

    et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521, 489–494 (2015).

  27. 27.

    et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451, 1116–1120 (2008).

  28. 28.

    et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111–1115 (2008).

  29. 29.

    et al. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J. Pathol. 229, 422–429 (2013).

  30. 30.

    et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol. 29, 3008–3015 (2011).

  31. 31.

    et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66, 8109–8115 (2006).

  32. 32.

    et al. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev. 25, 2158–2172 (2011).

  33. 33.

    , , & Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors. J. Biol. Chem. 289, 9247–9253 (2014).

  34. 34.

    et al. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. Cancer Res. 74, 287–297 (2014).

  35. 35.

    et al. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinogenesis 34, 739–749 (2013).

  36. 36.

    et al. A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. Oncogene 32, 5377–5387 (2013).

  37. 37.

    et al. Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. Ann. Oncol. 22, 1127–1132 (2011).

  38. 38.

    et al. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin. Mol. Cancer Ther. 10, 2000–2007 (2011).

  39. 39.

    The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011).

  40. 40.

    et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 1, 315–322 (2009).

  41. 41.

    et al. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients—a study of the tumour bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD). Eur. J. Cancer 50, 2090–2098 (2014).

  42. 42.

    et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, Fallopian tube, and peritoneal carcinomas. Clin. Cancer Res. 20, 764–775 (2014).

  43. 43.

    The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012).

  44. 44.

    et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486, 405–409 (2012).

  45. 45.

    et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400–404 (2012).

  46. 46.

    et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 12, 852–861 (2011).

  47. 47.

    et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb. Symp. Quant. Biol. 70, 139–148 (2005).

  48. 48.

    'Triple negative' breast cancer: a new area for phase III breast cancer clinical trials. Clin. Oncol. (R. Coll. Radiol.) 20, 35–39 (2008).

  49. 49.

    et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur. Urol. 63, 920–926 (2013).

  50. 50.

    et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215–1228 (2015).

  51. 51.

    et al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373, 1697–1708 (2015).

  52. 52.

    et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 16, 342–346 (2007).

  53. 53.

    et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2, 41–46 (2012).

  54. 54.

    et al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J. Clin. Oncol. 33, 3124–3129 (2015).

  55. 55.

    et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495–501 (2015).

  56. 56.

    et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399–405 (2012).

  57. 57.

    et al. Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines. Cell Cycle 13, 2129–2137 (2014).

  58. 58.

    et al. Concordance of ATM (ataxia telangiectasia mutated) immunohistochemistry between biopsy or metastatic tumor samples and primary tumors in gastric cancer patients. Pathobiology 80, 127–137 (2013).

  59. 59.

    The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43–49 (2013).

  60. 60.

    The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315–322 (2014).

  61. 61.

    The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543–550 (2014).

  62. 62.

    The Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67–73 (2013).

  63. 63.

    et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc. Natl Acad. Sci. USA 110, 18250–18255 (2013).

  64. 64.

    US National Library of Medicine. ClinicalTrials.gov , (2015).

  65. 65.

    , , , & A mutational signature in gastric cancer suggests therapeutic strategies. Nat. Commun. 6, 8683 (2015).

  66. 66.

    et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19, 664–678 (2011).

  67. 67.

    et al. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res. 72, 1608–1613 (2012).

  68. 68.

    et al. Targeting the DNA repair pathway in Ewing sarcoma. Cell Rep. 9, 829–841 (2014).

  69. 69.

    et al. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer 14, 813 (2014).

  70. 70.

    et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128, 157–170 (2007).

  71. 71.

    et al. PTEN C-terminal deletion causes genomic instability and tumor development. Cell Rep. 6, 844–854 (2014).

  72. 72.

    et al. Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. Science 341, 395–399 (2013).

  73. 73.

    et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N. Engl. J. Med. 368, 1101–1110 (2013).

  74. 74.

    et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313, 1347–1361 (2015).

  75. 75.

    et al. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J. Natl Cancer Inst. 94, 990–1000 (2002).

  76. 76.

    et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J. Clin. Oncol. 28, 3555–3561 (2010).

  77. 77.

    et al. Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling. PLoS ONE 8, e64268 (2013).

  78. 78.

    et al. Genome-wide transcriptome profiling of homologous recombination DNA repair. Nat. Commun. 5, 3361 (2014).

  79. 79.

    et al. Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. Breast Cancer Res. Treat. 135, 505–517 (2012).

  80. 80.

    et al. Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer. J. Natl Cancer Inst. 106, djt335 (2014).

  81. 81.

    et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).

  82. 82.

    et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979–993 (2012).

  83. 83.

    , , & Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res. 16, 211 (2014).

  84. 84.

    et al. Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations. PLoS ONE 8, e80023 (2013).

  85. 85.

    et al. The use of ovarian cancer cells from patients undergoing surgery to generate primary cultures capable of undergoing functional analysis. PLoS ONE 9, e90604 (2014).

  86. 86.

    et al. Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples. Br. J. Cancer 111, 94–100 (2014).

  87. 87.

    et al. An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer. Gynecol. Oncol. 134, 331–337 (2014).

  88. 88.

    et al. Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment. Clin. Cancer Res. 20, 4816–4826 (2014).

  89. 89.

    et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin. Cancer Res. 16, 6159–6168 (2010).

  90. 90.

    et al. Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. Ann. Oncol. 22, 870–876 (2011).

  91. 91.

    et al. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann. Oncol. 22, 1561–1570 (2011).

  92. 92.

    et al. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Res. 16, R47 (2014).

  93. 93.

    et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2, 366–375 (2012).

  94. 94.

    et al. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res. 16, 475 (2014).

  95. 95.

    et al. Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin. Cancer Res. 18, 5806–5815 (2012).

  96. 96.

    et al. Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark. Res. 3, 9 (2015).

  97. 97.

    et al. Genomic complexity profiling reveals that HORMAD1 overexpression contributes to homologous recombination deficiency in triple-negative breast cancers. Cancer Discov. 5, 488–505 (2015).

  98. 98.

    et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br. J. Cancer 107, 1776–1782 (2012).

  99. 99.

    et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res. 72, 5454–5462 (2012).

  100. 100.

    et al. Results of ARIEL2: a Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis. J. Clin. Oncol. 33 (Suppl), abstract 5508 (2015).

  101. 101.

    et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, l1 (2013).

  102. 102.

    et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).

Download references


The authors thank Breast Cancer Now, London, UK (formerly Breakthrough Breast Cancer and the Breast Cancer Campaign), Cancer Research UK; The Wellcome Trust, London, UK; The Breast Cancer Research Foundation, New York, USA; The Komen Foundation, Dallas, Texas, USA; and the University of California, San Francisco, USA for funding their work.

Author information


  1. Christopher J. Lord is at the Cancer Research UK Gene Function Laboratory and Breast Cancer Now Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.

    • Christopher J. Lord
  2. Alan Ashworth is at the UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94158, USA.

    • Alan Ashworth


  1. Search for Christopher J. Lord in:

  2. Search for Alan Ashworth in:

Competing interests

A.A. and C.J.L. are named inventors on patents describing the use of PARP inhibitors and as such stand to gain as part of the ICR 'Rewards to Inventors' Scheme.

Corresponding authors

Correspondence to Christopher J. Lord or Alan Ashworth.

Supplementary information

Excel files

  1. 1.

    Supplementary information S1 (table)

    Genes implicated in homologous recombination and/or PARP inhibitor sensitivity


Fanconi anaemia

(FA). A rare inherited disorder, normally diagnosed in children, in which the bone marrow does not produce key leukocyte lineages. Symptoms of FA include recurrent infections, a tendency to bleed easily and fatigue. Small skeletons and brown spots on the skin are also characteristics of FA, as is an enhanced predisposition to cancer.

Homologous recombination repair

(HRR). A form of DNA recombination often used to repair DNA double-strand breaks. HRR acts predominantly in the S and G2 phases of the cell cycle. Crucial proteins involved in mediating homologous recombination include those encoded by the BRCA1, BRCA2, RAD51 and partner and localizer of BRCA2 (PALB2) genes.

Loss of heterozygosity

(LOH). A situation in which an allele is lost, either by DNA recombination or by deletion, and the other allele is already deleted or mutated.

Maintenance therapy

A form of therapy used to enhance the overall effectiveness of a primary therapy. In most cases, maintenance therapy is given continuously after primary treatment to prevent or delay recurrence of disease.

Metagene signatures

Gene expression profiles derived from a panel of genes, as opposed to one gene, that correlate with clinical or biological phenotypes.

Non-homologous end joining

(NHEJ). A DNA repair mechanism that occurs throughout the cell cycle and directly ligates the ends of a DNA double-strand break (DSB) together. This process can cause the deletion or mutation of DNA sequences at or around the DSB site.

Odds ratio

A measure of the likelihood of an event happening in one group compared with a second group.

Panel sequencing

DNA sequencing that focuses on a subset of pre-defined genes or DNA regions, as opposed to sequencing of the entire exome or genome.

Pathological complete response

A clinical term defining the situation in which no histological signs of metastatic disease can be detected.

Synthetic lethal

Describes a form of genetic interaction. Two genes or proteins are synthetic lethal when inactivation of either one is compatible with cell viability but inactivation of both genes or proteins results in cell death.

About this article

Publication history